title: Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of montelukast 20 mg in the prophylactic treatment of migraine.
  
  
  BACKGROUND
  A previous small open-label study in migraine patients suggested prophylactic efficacy for montelukast, an antagonist of the cysteinyl leukotriene receptor that is used in the treatment of asthma. We sought to confirm these findings in a randomized controlled trial.
  
  
  METHODS
  This multicenter, randomized, double-blind, placebo-controlled, parallel-groups study enrolled adult migraine outpatients who experienced > or =3 and < or =8 migraine attacks per month for the last 6 months. Patients were entered into a 2-month, single-blind, placebo run-in phase. Only patients who experienced > or =3 migraine attacks in the second month were eligible to enter the subsequent 3-month, double-blind treatment phase of the study. The primary efficacy endpoint was the percentage of patients reporting at least a 50% decrease in migraine attack frequency per month during the double-blind treatment period (months 3-5) compared to baseline (run-in month 2).
  
  
  RESULTS
  A total of 93 patients were randomized to montelukast 20 mg and 84 patients to placebo at the end of the placebo run-in month 2; 76 patients on montelukast and 72 patients on placebo completed the double-blind treatment period. Over 3 months of treatment, there was no significant difference between the two groups in the percentage of patients who reported at least a 50% decrease in migraine attack frequency per month: 15.4% for montelukast versus 10.3% for placebo (P= .304). In addition, montelukast 20 mg was not significantly superior to placebo on any of the secondary endpoints. There were no differences between treatment groups for adverse events.
  
  
  CONCLUSIONS
  Montelukast 20 mg was well tolerated in migraine patients but was not an effective prophylactic for prevention of migraine.
authors.affiliation: Nashville Neuroscience Group, Nashville, TN, USA.
authors.forename: Jan L
authors.initials: JL
authors.lastname: Brandes
authors.forename: W Hester
authors.initials: WH
authors.lastname: Visser
authors.forename: Mildred V
authors.initials: MV
authors.lastname: Farmer
authors.forename: Amy L
authors.initials: AL
authors.lastname: Schuhl
authors.forename: William
authors.initials: W
authors.lastname: Malbecq
authors.forename: France
authors.initials: F
authors.lastname: Vrijens
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Lines
authors.forename: Scott A
authors.initials: SA
authors.lastname: Reines
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D003521:Cyclopropanes; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control*; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast